Maxwell Lee

PGY1 @StanfordOHNS | @CleClinicLCM '22 | @JohnsHopkins '17 | Views my own

[Maxwell Lee @MaxwellYLee]

Thrilled to have matched @StanfordOHNS for residency! Huge thank you to family, friends, and mentors @CleClinicLCM! #Otomatch #Match2022

[Samuel Chao @SamuelChaoMD]

AddThis | Home https://t.co/yk8wvZGmtl This is wonderful work by Max Lee, Zi Ouyang, Danielle LaHurd, @PhDpingxia, along with @DrEHBalagamwala, @DrJohnSuh, @AnthonyMagnelli, @SBalikPhD and @DrLilyAngelov. I love the collaboration with physics.

[Jeff Ryckman @jryckman3]

Great to see this #ASTRO19 abstract in full pub!

Recall: 24/1 may be assoc w vertebral compression fracture (VCF) rates of ~40%.

📌For 16-18 Gy, should we limit Dmax to 24 Gy (or consider 24/2)? 🤔
📌 MTT VCF ~1y (2y in Rose, 4mo in Sahgal).

#radonc https://t.co/65rN25Okpm

[Precigen @Precigen]

Read the newly published preclinical evaluation of #Precigen's PRGN-2012, a first-in-class investigational off-the-shelf AdenoVerse immunotherapy targeting infectious disease. View publication: https://t.co/rE6R4mbRxj $PGEN #Vaccine #InfectiousDisease

[Inigo Martincorena @imartincorena]

Excited to share our latest work. We present NanoSeq, a new duplex sequencing method with <5 errors per billion sites in single DNA molecules. A leap in our ability to study mutation in any tissue. 1/ https://t.co/QnrbVes3LA

[Maxwell Lee @MaxwellYLee]

Thrilled to finally share our work! We present PD-L1-targeting CAR NK cells as an "off the shelf" therapy that overcomes tumor heterogeneity when combined with T-cell immunotherapy in pre-clinical models.
Phase I/II clinical trials are already underway 📈📈📈

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells @MaxwellYLee https://t.co/0hItazOgM4

[Nature Medicine @NatureMedicine]

In a phase 1 trial of patients with #HPV-associated metastatic epithelial cancers, HPV-16 E7-specific #Tcells elicited objective clinical responses in 6 of 12 treated patients #cervicalcancer #HNSCC #NMedClinical @NCIResearchCtr @nciccr_gmb @CSHinrichsMD https://t.co/hgVf4vA7c5

[The Pittet Lab @PittetLab]

Great paper from Zemin Zhang lab in @CellCellPress presenting a single cell atlas of tumor infiltrating #myeloid cells across cancers https://t.co/p1XHDec2Xa
One key point: dendritic cell states are conserved across indications, which confirms our findings https://t.co/q9KZxEYef2

[Nature Portfolio @NaturePortfolio]

A paper published in Nature reports a single-cell multimodal imaging approach where genome organization, nuclear bodies, chromatin modifications and gene expression are determined in the same cell. https://t.co/lbPQ22ciN1

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies @gulleyj1 https://t.co/n49rvCK3hA

[Maxwell Lee @MaxwellYLee]

@JacobKnorr10 @SalamBachour @SpencerSeballos I'll man the Surface Hub John King style

[Maxwell Lee @MaxwellYLee]

@fjmay_7 @NIDCD @jitcancer Thanks Frank!

[Maxwell Lee @MaxwellYLee]

Happy to share our new article on antigen processing and presentation in cancer immunotherapy - a super exciting topic with lots of potential if taken advantage of! @NIDCD @jitcancer

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Antigen processing and presentation in cancer immunotherapy https://t.co/7uXFbexe5v

[Maxwell Lee @MaxwellYLee]

@ChanmiLee @NIDCD @jitcancer Thanks Chan Mi!

[Maxwell Lee @MaxwellYLee]

@JackMcVey14 @NIDCD @jitcancer Thanks Jack!

[Maxwell Lee @MaxwellYLee]

@LOConnor_ @NIDCD @jitcancer Thanks Luke!

[Maxwell Lee @MaxwellYLee]

Check out our @NIDCD recent article outlining the reasons why head and neck cancers may not respond to current immunotherapies. Looking forward to future research that addresses these challenges!

[AHNS @AHNSinfo]

https://t.co/yxrZR0JfH4 Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer

[NIH NIDCD @NIH_NIDCD]

NIDCD & @theNCI scientists have characterized immune cells that kill head & neck cancer cells in mice & reduce cells that allow tumors to escape immune response. https://t.co/kmPWTJOmPU #NIDCDresearch #hncsm @NIH @eLife

[Maxwell Lee @MaxwellYLee]

@paulcbryson @CCF_ent_program @_shadiam @HumzahQuereshy @jeremyruthberg Very grateful for the shout out, thanks for all that you do to help us students!